Indian investors at the Hong Kong Venture Capital & Private Equity Association’s (HKVCA) Asia Forum forecast rising opportunities for control deals in the early 2020s.
“If you go back and look at returns from private equity ... returns were good typically in periods when liquidity was low, valuations are benign and it gives you an opportunity to come in,” said Utsav...
Increased climate change awareness on a corporate level is leading to more investment – either direct or through funds – in start-ups that offer mitigation solutions. Asia is a key geography
Healthcare-focused Panacea Venture has led a $40 million Series C round for China’s XWPharma, a neurobiology-focused biotech developer previously known as XW Laboratories.
Kyee Technology, a Chinese digital medical platform has raised RMB430 million ($64 million) in a Series D round led by Tencent Holdings. Other investors include Longmen Capital, Dyee Capital and Royal Sea Capital.
Biocytogen, a Chinese contract research organization (CRO) that provides genetically-modified mice for drug testing, has raised RMB970 million ($143 million) in an extended tranche of Series D funding.